1. Home
  2. NCDL vs NTLA Comparison

NCDL vs NTLA Comparison

Compare NCDL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCDL
  • NTLA
  • Stock Information
  • Founded
  • NCDL 2019
  • NTLA 2014
  • Country
  • NCDL United States
  • NTLA United States
  • Employees
  • NCDL N/A
  • NTLA N/A
  • Industry
  • NCDL
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • NCDL
  • NTLA Health Care
  • Exchange
  • NCDL NYSE
  • NTLA Nasdaq
  • Market Cap
  • NCDL 770.8M
  • NTLA 794.5M
  • IPO Year
  • NCDL N/A
  • NTLA 2016
  • Fundamental
  • Price
  • NCDL $16.69
  • NTLA $9.20
  • Analyst Decision
  • NCDL Hold
  • NTLA Buy
  • Analyst Count
  • NCDL 3
  • NTLA 20
  • Target Price
  • NCDL $15.75
  • NTLA $36.60
  • AVG Volume (30 Days)
  • NCDL 195.6K
  • NTLA 6.0M
  • Earning Date
  • NCDL 08-06-2025
  • NTLA 08-07-2025
  • Dividend Yield
  • NCDL 10.89%
  • NTLA N/A
  • EPS Growth
  • NCDL N/A
  • NTLA N/A
  • EPS
  • NCDL N/A
  • NTLA N/A
  • Revenue
  • NCDL N/A
  • NTLA $45,569,000.00
  • Revenue This Year
  • NCDL N/A
  • NTLA N/A
  • Revenue Next Year
  • NCDL N/A
  • NTLA N/A
  • P/E Ratio
  • NCDL N/A
  • NTLA N/A
  • Revenue Growth
  • NCDL N/A
  • NTLA N/A
  • 52 Week Low
  • NCDL $14.21
  • NTLA $5.90
  • 52 Week High
  • NCDL $18.01
  • NTLA $28.18
  • Technical
  • Relative Strength Index (RSI)
  • NCDL 67.24
  • NTLA 57.28
  • Support Level
  • NCDL $16.16
  • NTLA $8.00
  • Resistance Level
  • NCDL $16.85
  • NTLA $10.52
  • Average True Range (ATR)
  • NCDL 0.26
  • NTLA 0.67
  • MACD
  • NCDL 0.05
  • NTLA 0.15
  • Stochastic Oscillator
  • NCDL 83.16
  • NTLA 63.35

About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP

Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: